Home › Funds › Eversept Partners, LP › ASND
Eversept Partners, LP position in ASND
ASCENDIS PHARMA A/S · Health Care
Eversept Partners, LP reported holding 41,621 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$11.1M, representing 0.58% of its reported portfolio and ranking #43 among its reported holdings. Eversept Partners, LP has disclosed ASND holdings in 2 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's ASND position evolved
Eversept Partners, LP first disclosed a stake in ASND in Q4 2025 at 48,241 shares (US$10.3M). The position peaked in Q2 2026 at 41,621 shares, worth US$11.1M. Across 2 filings, Eversept Partners, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 41,621 shares valued at US$11.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 48.24K | $10.29M | New |
| Q2 2026 | 41.62K | $11.10M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 43 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- RA CAPITAL MANAGEMENT, L.P. 10.28M sh · $2.74B · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.75M sh · $1.80B · Q2 2026
- Avoro Capital Advisors LLC 5.11M sh · $1.36B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 4.80M sh · $1.28B · Q2 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.63M sh · $702.55M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.16M sh · $310.39M · Q2 2026
- Vestal Point Capital, LP 375.00K sh · $100.02M · Q2 2026
- Tri Locum Partners LP 258.74K sh · $69.01M · Q2 2026
- ORBIMED ADVISORS LLC 244.46K sh · $65.20M · Q2 2026
- PFM Health Sciences, LP 233.17K sh · $62.19M · Q2 2026
- Frazier Life Sciences Management, L.P. 225.16K sh · $60.05M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held ASND?
Eversept Partners, LP has disclosed ASND holdings in 2 of the last 3 reported quarters, going back to Q4 2025.
What is Eversept Partners, LP's current position in ASND?
As of Q2 2026, Eversept Partners, LP holds 41.62K shares of ASND (ASCENDIS PHARMA A/S), valued at $11.10M, representing 0.58% of its reported portfolio and ranking #43.
Has Eversept Partners, LP been buying or selling ASND?
In the latest 13F filing (Q2 2026), Eversept Partners, LP newly opened its position in ASND. The position peaked in Q2 2026 at 41.62K shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.